Cancer/Gene Therapy

Retroviral-Mediated Gene Transfer Enhances Antitumor Immunity

Published in Cancer Weekly, March 6th, 1995

Researchers determine that a better antitumor response can be generated by tumor vaccines by introducing xenogeneic class II major histocompatibility complex (MHC) genes into the tumor cells.

Randy A. Hock et al. report that many studies that have introduced class I and II MHC genes into tumor cells have used inefficient methods that required extensive cloning of the tumor cells before using them as vaccines ("Human Class II Major Histocompatibility Complex Gene Transfer into Murine Neuroblastoma Leads to Loss of Tumorigenicity, Immunity Against Subsequent Tumor Challenge, and Elimination of Microscopic Preestablished Tumors," Journal of Immunotherapy,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry